Year Year arrow
arrow-active-down-0
Publisher Publisher arrow
arrow-active-down-1
Journal
1
Journal arrow
arrow-active-down-2
Institution Institution arrow
arrow-active-down-3
Institution Country Institution Country arrow
arrow-active-down-4
Publication Type Publication Type arrow
arrow-active-down-5
Field Of Study Field Of Study arrow
arrow-active-down-6
Topics Topics arrow
arrow-active-down-7
Open Access Open Access arrow
arrow-active-down-8
Language Language arrow
arrow-active-down-9
Filter Icon Filter 1
Year Year arrow
arrow-active-down-0
Publisher Publisher arrow
arrow-active-down-1
Journal
1
Journal arrow
arrow-active-down-2
Institution Institution arrow
arrow-active-down-3
Institution Country Institution Country arrow
arrow-active-down-4
Publication Type Publication Type arrow
arrow-active-down-5
Field Of Study Field Of Study arrow
arrow-active-down-6
Topics Topics arrow
arrow-active-down-7
Open Access Open Access arrow
arrow-active-down-8
Language Language arrow
arrow-active-down-9
Filter Icon Filter 1
Export
Sort by: Relevance
  • Open Access Icon
  • Retracted
  • Addendum
  • 10.1159/000544828
Retraction Statement
  • Apr 11, 2025
  • Pharmacology

  • Open Access Icon
  • Research Article
  • Cite Count Icon 12
  • 10.1159/000545659
Inhibition of Interleukin-8/C-X-C Chemokine Receptor 2 Signaling Axis Prevents Tumor Growth and Metastasis in Triple-Negative Breast Cancer Cells
  • Apr 4, 2025
  • Pharmacology
  • Yisun Jeong + 5 more

  • Supplementary Content
  • 10.1159/000545763
Front & Back Matter
  • Apr 1, 2025
  • Pharmacology

  • Research Article
  • 10.1159/000545370
UBE2K Facilitates Erlotinib Resistance and Induces Epithelial Mesenchymal Transition in Osteosarcoma Cancer Stem-Like Cells via Activating the mTOR Signaling
  • Mar 28, 2025
  • Pharmacology
  • Tian Wang + 4 more

  • Research Article
  • 10.1159/000543902
Batryticatus bombyx Improved Atopic Dermatitis in NC/Nga Mice and Impact on Inflammation and Recovery of Skin Barrier via STAT1/P38/NF-ÎşB Downregulation and HO-1/Nrf2 Activation in HaCaT Keratinocytes
  • Feb 5, 2025
  • Pharmacology
  • Gunhyuk Park + 3 more

  • Research Article
  • Cite Count Icon 3
  • 10.1159/000543234
Pharmacological Characterization of GB1908, a Selective Galectin-1 Carbohydrate Binding Domain Inhibitor for the Treatment of Cancer
  • Feb 3, 2025
  • Pharmacology
  • Kimberly D Herman + 8 more

  • Supplementary Content
  • 10.1159/000544015
Front & Back Matter
  • Feb 1, 2025
  • Pharmacology

  • Research Article
  • Cite Count Icon 1
  • 10.1159/000543797
Estrogen Receptors and Platelet-Activating Acetylhydrolase Activity in the Pathogenesis of Systemic Lupus Erythematosus
  • Jan 27, 2025
  • Pharmacology
  • Akira Sato + 5 more

  • Research Article
  • 10.1159/000543416
Safety, Tolerability, Pharmacokinetics, and Effects of Gene Polymorphisms on Furaprevir (TG-2349), a Novel Hepatitis C Inhibitor: A Randomized Phase I Study
  • Jan 20, 2025
  • Pharmacology
  • Su-Mei Xu + 5 more

  • Research Article
  • Cite Count Icon 1
  • 10.1159/000543293
Nephroprotective Effects of Curcumin in Murine Models of Focal and Segmental Glomerulosclerosis
  • Jan 8, 2025
  • Pharmacology
  • Sufia Husain + 3 more